oncosec medical inc (ONCS) Key Developments
OncoSec Medical Announces Positive Interim Data from Phase II Melanoma Study
Jun 25 14
OncoSec Medical Inc. has announced positive interim data from a Phase II study of ImmunoPulse in patients with advanced melanoma. Data from the multicenter, open-label, single-arm study confirmed the safety of OncoSec's lead product candidate, ImmunoPulse, which delivers the anti-tumor agent pIL-12 directly into the tumor via in-vivo electroporation (EP), with no treatment-related serious adverse events or deaths having been reported. Regression of treated and non-treated tumors suggests successful induction of systemic anti-tumor response. To date, 30 patients have been enrolled and have received at least one cycle of treatment. At the time of this interim analysis, 28 patients were evaluable for objective response rate (ORR) at 24-week primary time point.
OncoSec Medical Inc. Appoints Dr. Soldano Ferrone to Scientific Advisory Board
Jun 25 14
OncoSec Medical Inc. has appointed Dr. Soldano Ferrone, M.D., Ph.D., to the company's Scientific Advisory Board. Dr. Ferrone is an internationally renowned expert in tumor immunology, and will contribute his considerable expertise to the company as it works to advance an expanding intratumoral immunotherapy pipeline.
OncoSec Medical Incorporated Presents at BIO International Convention, Jun-25-2014 02:45 PM
Jun 17 14
OncoSec Medical Incorporated Presents at BIO International Convention, Jun-25-2014 02:45 PM. Venue: San Diego Convention Center, San Diego, California, United States.
OncoSec Medical Inc. Announces Earnings Results for the Nine Months Ended April 30, 2014
Jun 13 14
OncoSec Medical Inc. announced earnings results for the nine months ended April 30, 2014. For the period, the company reported a net loss of $8.5 million, or $0.05 per share, compared to a net loss of $5.4 million, or $0.05 per share, for the same period last year. There were no revenues for the nine months ended April 30, 2014 or April 30, 2013.
OncoSec Medical Incorporated, Annual General Meeting, Jul 18, 2014
Jun 6 14
OncoSec Medical Incorporated, Annual General Meeting, Jul 18, 2014., at 09:00 Pacific Standard Time. Location: Principal Executive Offices. Agenda: To elect four directors to Board of Directors to serve for a term of one year or until their successors are duly elected and qualified; to ratify the appointment of Mayer Hoffman McCann P.C. as the company's independent registered public accounting firm for the fiscal year ending July 31, 2014; to approve the amendment and restatement of the company's 2011 Stock Incentive Plan to, among other things, authorize the issuance of an additional 16,000,000 shares of common stock under the 2011 Plan; and to transact other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.